My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C100P Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody 1 mg 295.00
C100P Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody 5 mg 995.00
C100P Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody 20 mg 2950.00
C100P Afucosylated Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody 1 mg 495.00
Description

C100P: Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Recombinant Human IgG1 Kappa Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-SARS-CoV-2 spike monoclonal antibody casirivimab biosimilar was produced in the casirivimab biosimilar CHO cells.
Specificity/Sensitivity: The casirivimab biosimilar specifically binds to the spike protein of SARS-CoV-2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by casirivimab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing condition.

Shipping: The research grade casirivimab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is casirivimab biosimilar research grade? Casirivimab is a human monoclonal antibody directed against the spike protein of SARS-CoV-2. Casirivimab is a human monoclonal antibody (IgG1κ isotype). Casirivimab biosimilar uses the same protein sequences as the therapeutic antibody casirivimab. Casirivimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. Casirivimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar.

Syd Labs also provides the following research grade anti-SARS-CoV-2 spike antibody biosimilar proteins:
Sotrovimab biosimilar, research grade, SARS-CoV-2 spike monoclonal antibody

Related Links

See our Privacy Policy